TNFRSF4 and neoplasm: To support our ongoing clinical trial evaluating an anti-OX40 antibody, we next asked if treatment with this T cell costimulatory receptor agonist (also capable of depleting OX40 enriched cells through Fc receptor interactions) induces different responses in these four different tumor microenvironments.